Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J A Conti

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Surgical Endoscopy|February 14, 2018
EAES classification of intraoperative adverse events in laparoscopic surgeryN K Francis, N J Curtis, J A Conti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1992
Biochemical modulation of bolus fluorouracil by PALA in patients with advanced colorectal cancerN Kemeny, J A Conti, K Seiter, et al.
Colorectal Disease : the Official Journal of the Association of Coloproctology of Great Britain and Ireland|December 23, 2011
The selective use of splenic flexure mobilization is safe in both laparoscopic and open anterior resectionsM R Marsden, J A Conti, S Zeidan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1993
Randomized trial of hepatic arterial floxuridine, mitomycin, and carmustine versus floxuridine alone in previously treated patients with liver metastases from colorectal cancerN Kemeny, A Cohen, K Seiter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1994
Phase II study of hepatic arterial floxuridine, leucovorin, and dexamethasone for unresectable liver metastases from colorectal carcinomaN Kemeny, J A Conti, A Cohen, et al.
Cancer|March 15, 1993
A pilot study of hepatic artery floxuridine combined with systemic 5-fluorouracil and leucovorin. A potential adjuvant program after resection of colorectal hepatic metastasesN Kemeny, J A Conti, E Sigurdson, et al.
Cancer|February 1, 1995
A fixed-ratio combination of uracil and Ftorafur (UFT) with low dose leucovorin. An active oral regimen for advanced colorectal cancerL B Saltz, C G Leichman, C W Young, et al.
Techniques in Coloproctology|May 8, 2016
Application of objective clinical human reliability analysis (OCHRA) in assessment of technical performance in laparoscopic rectal cancer surgeryJ D Foster, D Miskovic, A S Allison, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1996
Irinotecan is an active agent in untreated patients with metastatic colorectal cancerJ A Conti, N E Kemeny, L B Saltz, et al.
Cancer|February 15, 1994
Hepatic arterial floxuridine and leucovorin for unresectable liver metastases from colorectal carcinoma. New dose schedules and survival updateN Kemeny, K Seiter, J A Conti, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Surgical Endoscopy|February 14, 2018
EAES classification of intraoperative adverse events in laparoscopic surgeryN K Francis, N J Curtis, J A Conti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1992
Biochemical modulation of bolus fluorouracil by PALA in patients with advanced colorectal cancerN Kemeny, J A Conti, K Seiter, et al.
Colorectal Disease : the Official Journal of the Association of Coloproctology of Great Britain and Ireland|December 23, 2011
The selective use of splenic flexure mobilization is safe in both laparoscopic and open anterior resectionsM R Marsden, J A Conti, S Zeidan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1993
Randomized trial of hepatic arterial floxuridine, mitomycin, and carmustine versus floxuridine alone in previously treated patients with liver metastases from colorectal cancerN Kemeny, A Cohen, K Seiter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1994
Phase II study of hepatic arterial floxuridine, leucovorin, and dexamethasone for unresectable liver metastases from colorectal carcinomaN Kemeny, J A Conti, A Cohen, et al.
Cancer|March 15, 1993
A pilot study of hepatic artery floxuridine combined with systemic 5-fluorouracil and leucovorin. A potential adjuvant program after resection of colorectal hepatic metastasesN Kemeny, J A Conti, E Sigurdson, et al.
Cancer|February 1, 1995
A fixed-ratio combination of uracil and Ftorafur (UFT) with low dose leucovorin. An active oral regimen for advanced colorectal cancerL B Saltz, C G Leichman, C W Young, et al.
Techniques in Coloproctology|May 8, 2016
Application of objective clinical human reliability analysis (OCHRA) in assessment of technical performance in laparoscopic rectal cancer surgeryJ D Foster, D Miskovic, A S Allison, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1996
Irinotecan is an active agent in untreated patients with metastatic colorectal cancerJ A Conti, N E Kemeny, L B Saltz, et al.
Cancer|February 15, 1994
Hepatic arterial floxuridine and leucovorin for unresectable liver metastases from colorectal carcinoma. New dose schedules and survival updateN Kemeny, K Seiter, J A Conti, et al.
Pageof 4